Ezio Bonifacio

Ezio Bonifacio

Auto-generated profile, based on publicly available information

Ezio Bonifacio

German Center for Diabetes Research (DZD) Munich Germany

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2013 in JAMA
Verified
Journal Article
Open access
PDF file
AZAnette G. Ziegler
Anette G. Ziegler
MRMarian Rewers
Marian Rewers
OSOlli Simell
Olli Simell
TSTuula Simell
Tuula Simell
JLJohanna Lempainen
Johanna Lempainen
GEGeorge S. Eisenbarth
George S. Eisenbarth
Type 1 diabetes is a chronic autoimmune disease that often manifests during childhood and adolescence.1 The lifelong requirement for insulin injections and the many complications that follow the diagnosis can be difficult for those affected.2 Type 1 diabetes usually has a preclinical phase that can be identified by the presence of autoantibodies to antigens of the pancreatic β cells.

15 December 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
JSJay S. Skyler
Jay S. Skyler
GBGeorge L. Bakris
George L. Bakris
EBEzio Bonifacio
Ezio Bonifacio
TDTamara Darsow
Tamara Darsow
RERobert H. Eckel
Robert H. Eckel
RRRobert E. Ratner
Robert E. Ratner
The American Diabetes Association, JDRF, the European Association for the Study of Diabetes, and the American Association of Clinical Endocrinologists convened a research symposium, “The Differentiation of Diabetes by Pathophysiology, Natural History and Prognosis” on 10–12 October 2015. International experts in genetics, immunology, metabolism, endocrinology, and systems biology discussed genetic and environmental determinants of type 1 and type 2 diabetes risk and progression, as well as complications. The participants debated how to determine appropriate therapeutic approaches based on disease pathophysiology and stage and defined remaining research gaps hindering a personalized medical approach for diabetes to drive the field to address these gaps. The authors recommend a structure for data stratification to define the phenotypes and genotypes of subtypes of diabetes that will facilitate individualized treatment.

1 March 1999 in Diabetes
Verified
Journal Article
Closed access
PDF file
AZA G Ziegler
A G Ziegler
MHM Hummel
M Hummel
MSM Schenker
M Schenker
EBE Bonifacio
E Bonifacio
The temporal development of autoantibodies was studied in 1,353 offspring of parents with type 1 diabetes. Islet cell antibodies (ICAs) and autoantibodies to insulin (IAAs), glutamic acid decarboxylase, and IA-2 were measured at birth, 9 months, 2 years, and 5 years of age. At birth, no offspring had islet autoimmunity other than maternally acquired antibodies, which were shown to influence antibody prevalence up to age 6 months. Antibodies detected thereafter were likely to represent a true de novo production, since prevalences were the same for offspring from mothers and fathers with diabetes, antibodies detected at 9 months were almost always confirmed in the 2-year sample and were associated with an increased likelihood of having or developing other antibodies. By 2 years of age, autoantibodies appeared in 11% of offspring, 3.5% having more than one autoantibody. IAAs were detected most frequently, and few had autoantibodies in the absence of IAAs. In 23 offspring with multiple islet autoantibodies, IAAs preceded other antibodies in 10 cases and were first detected concurrently with other antibodies in 12 and after detection of other antibodies in 1. Development of additional antibodies and changes in levels, including decline of IAAs at older age, was frequent. Nine children, all with IAAs and ICAs, developed diabetes. Overall cumulative risk for disease by 5 years of age was 1.8% (95% CI 0.2-3.4) and was 50% (95% CI 19-81) for offspring with more than one autoantibody in their 2-year sample. Autoimmunity associated with childhood diabetes is an early event and a dynamic process. Presence of IAAs is a consistent feature of this autoimmunity, and IAA detection can identify children at risk.

15 July 2005 in Blood
Verified
Journal Article
Closed access
PDF file
VSValeria Sordi
Valeria Sordi
MMMARIA LUISA MALOSIO
MARIA LUISA MALOSIO
FMFederica Marchesi
Federica Marchesi
AMAlessia Mercalli
Alessia Mercalli
RMRaffaella Melzi
Raffaella Melzi
LPLorenzo Piemonti
Lorenzo Piemonti
Bone marrow–derived mesenchymal stem cells (BM-MSCs) are stromal cells with the ability to proliferate and differentiate into many tissues. Although they represent powerful tools for several therapeutic settings, mechanisms regulating their migration to peripheral tissues are still unknown. Here, we report chemokine receptor expression on human BM-MSCs and their role in mediating migration to tissues. A minority of BM-MSCs (2% to 25%) expressed a restricted set of chemokine receptors (CXC receptor 4 [CXCR4], CX3C receptor 1 [CX3CR1], CXCR6, CC chemokine receptor 1 [CCR1], CCR7) and, accordingly, showed appreciable chemotactic migration in response to the chemokines CXC ligand 12 (CXCL12), CX3CL1, CXCL16, CC chemokine ligand 3 (CCL3), and CCL19. Using human pancreatic islets as an in vitro model of peripheral tissue, we showed that islet supernatants released factors able to attract BM-MSCs in vitro, and this attraction was principally mediated by CX3CL1 and CXCL12. Moreover, cells with features of BM-MSCs were detected within the pancreatic islets of mice injected with green fluorescent protein (GFP)–positive BM. A population of bona fide MSCs that also expressed CXCR4, CXCR6, CCR1, and CCR7 could be isolated from normal adult human pancreas. This study defines the chemokine receptor repertoire of human BM-MSCs that determines their migratory activity. Modulation of homing capacity may be instrumental for harnessing the therapeutic potential of BM-MSCs.

1 October 2003 in JAMA
Verified
Journal Article
Closed access
PDF file
AZAnette-G. Ziegler
Anette-G. Ziegler
SSSandra Schmid
Sandra Schmid
DHDoris Huber
Doris Huber
MHMichael Hummel
Michael Hummel
EBEzio Bonifacio
Ezio Bonifacio
Research from JAMA — Early Infant Feeding and Risk of Developing Type 1 Diabetes–Associated Autoantibodies — ContextDietary factors modifying type 1 diabetes mellitus (DM) risk have been proposed, but little is known if they trigger the islet autoimmunity that precedes clinical disease.ObjectiveTo determine whether breastfeeding duration, food supplementation, or age at introduction of gluten-containing foods influences the risk of developing islet autoantibodies.Design and SettingProspective natural history cohort study conducted from 1989 to 2003 in inpatient/outpatient clinics in Germany.ParticipantsThe BABYDIAB study follows newborn children of parents with type 1 DM. Eligibility requirements were met in 1610 children. Blood samples were obtained at birth, age 9 months, 2, 5, and 8 years. Dropout rate was 14.4% by age 5 years. Breastfeeding data were obtained by prospective questionnaires (91% complete), and food supplementation data were obtained by family interview (72% for food supplementation and 80% for age of gluten introduction).Main Outcome MeasureDevelopment of islet autoantibodies (insulin, glutamic acid decarboxylase, or IA-2 antibodies) in 2 consecutive blood samples.ResultsLife-table islet autoantibody frequency was 5.8% (SE, 0.6%) by age 5 years. Reduced total or exclusive breastfeeding duration did not significantly increase the risk of developing islet autoantibodies. Food supplementation with gluten-containing foods before age 3 months, however, was associated with significantly increased islet autoantibody risk (adjusted hazard ratio, 4.0; 95% confidence interval, 1.4-11.5; P = .01 vs children who received only breast milk until age 3 months). Four of 17 children who received gluten foods before age 3 months developed islet autoantibodies (life-table 5-year risk, 24%; SE, 10%). All 4 children had the high-risk DRB1*03/04,DQB1*0302 genotype. Early exposure to gluten did not significantly increase the risk of developing celiac disease–associated autoantibodies. Children who first received gluten foods after age 6 months did not have increased risks for islet or celiac disease autoantibodies.ConclusionEnsuring compliance to infant feeding guidelines is a possible way to reduce the risk of development of type 1 DM autoantibodies.

14 June 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
RFRicardo C. Ferreira
Ricardo C. Ferreira
HGHui Guo
Hui Guo
RCRichard M.R. Coulson
Richard M.R. Coulson
DSDeborah J. Smyth
Deborah J. Smyth
MPMarcin L. Pekalski
Marcin L. Pekalski
AZAnette-G. Ziegler
Anette-G. Ziegler
Diagnosis of the autoimmune disease type 1 diabetes (T1D) is preceded by the appearance of circulating autoantibodies to pancreatic islets. However, almost nothing is known about events leading to this islet autoimmunity. Previous epidemiological and genetic data have associated viral infections and antiviral type I interferon (IFN) immune response genes with T1D. Here, we first used DNA microarray analysis to identify IFN-β–inducible genes in vitro and then used this set of genes to define an IFN-inducible transcriptional signature in peripheral blood mononuclear cells from a group of active systemic lupus erythematosus patients (n = 25). Using this predefined set of 225 IFN signature genes, we investigated the expression of the signature in cohorts of healthy controls (n = 87), patients with T1D (n = 64), and a large longitudinal birth cohort of children genetically predisposed to T1D (n = 109; 454 microarrayed samples). Expression of the IFN signature was increased in genetically predisposed children before the development of autoantibodies (P = 0.0012) but not in patients with established T1D. Upregulation of IFN-inducible genes was transient, temporally associated with a recent history of upper respiratory tract infections (P = 0.0064), and marked by increased expression of SIGLEC-1 (CD169), a lectin-like receptor expressed on CD14+ monocytes. DNA variation in IFN-inducible genes altered T1D risk (P = 0.007), as exemplified by IFIH1, one of the genes in our IFN signature for which increased expression is a known risk factor for disease. These findings identify transient increased expression of type I IFN genes in preclinical diabetes as a risk factor for autoimmunity in children with a genetic predisposition to T1D.